These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25015634)

  • 21. Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.
    Collier P; Patel K; Waeltz P; Rupar M; Luthra R; Liu PC; Hollis G; Huber R; Verstovsek S; Burn TC
    Genet Test Mol Biomarkers; 2013 May; 17(5):429-37. PubMed ID: 23537216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation.
    Er TK; Lin SF; Chang JG; Hsieh LL; Lin SK; Wang LH; Lin CW; Chang CS; Liu TC
    Clin Chim Acta; 2009 Oct; 408(1-2):39-44. PubMed ID: 19595684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.
    Merker JD; Jones CD; Oh ST; Schrijver I; Gotlib J; Zehnder JL
    J Mol Diagn; 2010 Jan; 12(1):58-64. PubMed ID: 19959796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Establishment of a system for rapid detection of JAK2 V617F mutation in myeloproliferative diseases].
    Zhang Q; Zhang Y; Xu X; Zhou W; Fan X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Oct; 36(10):980-984. PubMed ID: 31598940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The development and comparative approbation of methods of increasing sensitivity of detection of mutation V617F in gene JAK2 by pyro-sequencing].
    Dunaeva EA; Mironov KO; Subbotina TN; Olkhovsky IA; Shipulin GA
    Klin Lab Diagn; 2017 Feb; 62(2):125-8. PubMed ID: 30615403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
    Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
    BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
    Masykura N; Habibah U; Selasih SF; Gani S; Irawan C; Somoastro S; Handoyo Utomo AR
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):220-227. PubMed ID: 30772299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.
    Mercier F; Monczak Y; François M; Prchal J; Galipeau J
    Exp Hematol; 2009 Mar; 37(3):416-20. PubMed ID: 19135773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis.
    Lay M; Mariappan R; Gotlib J; Dietz L; Sebastian S; Schrijver I; Zehnder JL
    J Mol Diagn; 2006 Jul; 8(3):330-4. PubMed ID: 16825505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK2 V617F mutation detection: laboratory comparison of two kits using RFLP and qPCR.
    Shammaa D; Bazarbachi A; Halas H; Greige L; Mahfouz R
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):13-5. PubMed ID: 19877761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Automated JAK2V617F quantification using a magnetic filtration system and sequence-specific primer-single molecule fluorescence detection.
    Ohyashiki K; Hori K; Makino T; Ohyashiki JH
    Cancer Genet Cytogenet; 2007 Nov; 179(1):19-24. PubMed ID: 17981210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of
    Chen M; Zhang C; Hu Z; Li Z; Li M; Wu L; Zhou M; Liang D
    Biosensors (Basel); 2021 Jul; 11(8):. PubMed ID: 34436049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.
    Takahashi K; Patel KP; Kantarjian H; Luthra R; Pierce S; Cortes J; Verstovsek S
    Blood; 2013 Nov; 122(23):3784-6. PubMed ID: 24068492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JAK2 V617F mutation can be reliably detected in serum using droplet digital PCR.
    Nystrand CF; Ghanima W; Waage A; Jonassen CM
    Int J Lab Hematol; 2018 Apr; 40(2):181-186. PubMed ID: 29150911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms.
    Fontanelli G; Baratè C; Ciabatti E; Guerrini F; Grassi S; Del Re M; Morganti R; Petrini I; Arici R; Barsotti S; Metelli MR; Danesi R; Galimberti S
    Int J Lab Hematol; 2015 Dec; 37(6):766-73. PubMed ID: 26189968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection.
    Zapparoli GV; Jorissen RN; Hewitt CA; McBean M; Westerman DA; Dobrovic A
    BMC Cancer; 2013 Apr; 13():206. PubMed ID: 23617802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
    Szpurka H; Tiu R; Murugesan G; Aboudola S; Hsi ED; Theil KS; Sekeres MA; Maciejewski JP
    Blood; 2006 Oct; 108(7):2173-81. PubMed ID: 16741247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD).
    Koren-Michowitz M; Shimoni A; Vivante A; Trakhtenbrot L; Rechavi G; Amariglio N; Loewenthal R; Nagler A; Cohen Y
    Leuk Res; 2008 Mar; 32(3):421-7. PubMed ID: 17698191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.